Acotiamide hydrochloride hydrate + Placebo

Phase 3Active
0 views this week 0 watching Active
Interest: 44/100
44
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Functional Dyspepsia

Conditions

Functional Dyspepsia

Trial Timeline

Feb 22, 2021 → Jun 1, 2026

About Acotiamide hydrochloride hydrate + Placebo

Acotiamide hydrochloride hydrate + Placebo is a phase 3 stage product being developed by Zeria Pharmaceutical for Functional Dyspepsia. The current trial status is active. This product is registered under clinical trial identifier NCT04526119. Target conditions include Functional Dyspepsia.

What happened to similar drugs?

0 of 5 similar drugs in Functional Dyspepsia were approved

Approved (0) Terminated (1) Active (4)
🔄Imonogas + EspumisanJohnson & JohnsonPhase 3
🔄Linaclotide + PlaceboAbbViePhase 3
Gabapentin + PlaceboPfizerPhase 3
🔄Z-338 + PlaceboZeria PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04526119Phase 3Active